Search

Etrasimod

[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis. … [A261826] In fact, it has been observed that antigen-activated T cells within peripheral lymphoid organs can transiently downregulate S1P receptor levels to facilitate immune cells trafficking into the

Ponesimod

[A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709] … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].

Norethynodrel

It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.

Difamilast

[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production

Phosphocreatine

It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to

Opaganib

Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. … [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

Nedocromil

A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.

Phenoxybenzamine

It has been used to treat hypertension and as a peripheral vasodilator.

Florquinitau (18F)

[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer.

Sodium phosphate, dibasic